Physician profile

Doris Cope

Pain Medicine · Pooler, GA

NPI 1376515932

$796.83

in general payments reported to CMS, 2019-2025

9 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Consulting Fee$325.33
Food and Beverage$55.54

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Vertex Pharmaceuticals Incorporated $325.33 2024
Boston Scientific Corporation $263.88 2020-2023 Wavewriter Alpha Prime 16
Abbott Laboratories $58.41 2021-2023 Proclaim
Relievant Medsystems, INC. $37.40 2022
Medtronic, INC. $32.48 2022
Forte Bio-Pharma LLC $26.52 2020
Pacira Therapeutics, INC. $20.66 2021
Collegium Pharmaceutical, INC. $16.67 2022
Stimwave Technologies Incorporated $15.48 2022

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Doris Cope

$796.83

in general payments reported 2019-2025

Years
2020-2024
Top company
Vertex Pharmaceuticals Incorporated

https://glasscript.com/doctor/243348/doris-cope

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.